Recombinant Human Interleukin-2 receptor subunit alpha (IL2RA)

What is the molecular structure of human IL2RA?

Human IL2RA (CD25) is a 55 kDa membrane glycoprotein that functions as the alpha subunit of the IL-2 receptor complex. The protein is encoded by a 272 amino acid residue precursor with distinct structural regions: a 21 residue signal peptide, a 219 residue extracellular domain, a 19 residue transmembrane region, and a 13 residue cytoplasmic domain. Unlike other cytokine receptor family members, IL2RA lacks characteristic structural features of the cytokine receptor superfamily. The mature protein spans from Glu22 to Cys213 in the extracellular region. The theoretical isoelectric point (pI) is approximately 6.49, reflecting its charge properties .

How does IL2RA interact with other IL-2 receptor subunits to form functional receptors?

IL2RA interacts with IL-2 receptor beta (IL2RB) and common gamma chain (γc) subunits to form the high-affinity IL-2 receptor complex. By itself, IL2RA binds IL-2 with low affinity (Kd ~10⁻⁸ M), while IL2RB and γc together form an intermediate-affinity receptor (Kd ~10⁻⁹ M). When all three subunits assemble, they create the high-affinity IL-2 receptor (Kd ~10⁻¹¹ M). The high-affinity binding results from IL-2's rapid association and dissociation rates with IL2RA coupled with slower kinetics with the intermediate-affinity receptor components. When IL2RA and IL2RB are co-expressed without γc, they form a "pseudo-high affinity" binding (Kd ~10⁻¹⁰ M) but no signaling occurs since functional signaling requires heterodimerization of IL2RB and γc cytoplasmic domains .

What are the key functional roles of IL2RA in immune regulation?

IL2RA plays essential roles in immune regulation, particularly in controlling regulatory T cell (Treg) activity. The receptor participates in mediating immune tolerance by suppressing the activation and expansion of autoreactive T cells. It is critically involved in IL-2-mediated signaling pathways that regulate T cell proliferation, particularly activated CD4-positive, alpha-beta T cells. Beyond merely concentrating IL-2 at the cell surface, IL2RA actively contributes to IL-2 signaling by altering the functional capacity of IL2RB and enhancing its affinity for IL-2. This affinity conversion occurs even without prior binding of IL-2 to IL2RA, suggesting a more complex role in signal transduction than previously understood .

What formulations of recombinant human IL2RA are available for research, and how do they differ?

Recombinant human IL2RA is available in multiple formulations optimized for different experimental applications. Two common formulations include those with carrier proteins (typically bovine serum albumin, BSA) and carrier-free versions. The standard formulation (e.g., 223-2A) is lyophilized from a 0.2 μm filtered PBS solution containing BSA as a carrier protein, while carrier-free formulations (e.g., 223-2A/CF) are lyophilized from filtered PBS without BSA. The carrier protein enhances stability, increases shelf-life, and allows storage at more dilute concentrations. Carrier-free versions are recommended for applications where BSA could interfere with experimental outcomes. Both formulations require proper reconstitution—the standard version at 10 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin, and the carrier-free version at 50 μg/mL in sterile PBS .

What expression systems are used to produce recombinant IL2RA, and how do they affect protein properties?

Recombinant human IL2RA can be produced in various expression systems, with HEK 293 cells being a common mammalian expression platform. This system offers advantages for producing human proteins with proper post-translational modifications, particularly glycosylation patterns that may be critical for IL2RA functionality. Recombinant IL2RA produced in mammalian systems typically achieves ≥80% purity and is suitable for applications such as SDS-PAGE and sandwich ELISA. These expression systems can generate protein fragments (such as the extracellular domain) with tags (e.g., His tag) for purification and detection. The expression system choice significantly impacts protein folding, glycosylation patterns, and biological activity, with mammalian systems generally preferred for maintaining native-like properties for immunological studies .

How should recombinant IL2RA be stored and handled to maintain optimal activity?

To maintain optimal activity of recombinant IL2RA, proper storage and handling protocols are essential. Upon receipt, the lyophilized protein should be immediately stored at recommended temperatures. For long-term storage, a manual defrost freezer is recommended to avoid repeated freeze-thaw cycles, which can significantly compromise protein integrity and activity. When reconstituting lyophilized IL2RA, researchers should use sterile PBS with appropriate protein concentrations as specified by the manufacturer (10 μg/mL for standard formulations or 50 μg/mL for carrier-free versions). Once reconstituted, aliquoting the protein into single-use volumes helps minimize freeze-thaw cycles. Working solutions should be prepared fresh and maintained at appropriate temperatures as specified in experimental protocols. For shipping and temporary storage, ambient temperature is typically suitable, but long-term stability requires proper freezer storage .

What are the recommended protocols for using recombinant IL2RA in cell-based assays?

For cell-based assays, recombinant IL2RA should be incorporated following validated protocols to ensure experimental validity. When using IL2RA to study T cell activation or proliferation, researchers should first determine the optimal concentration range through dose-response experiments. Typically, effective concentrations range from 0.15-0.75 μg/mL when used in conjunction with 30 ng/mL of recombinant human IL-2. For receptor-ligand interaction studies, freshly reconstituted protein yields the most consistent results. When designing blocking experiments, consider that IL2RA acts not merely as a passive IL-2 concentrator but actively alters IL2RB function. In competitive binding assays, researchers should account for the differential binding affinities of the various receptor complexes (low, intermediate, and high-affinity). For accurate assessment of IL2RA functionality in regulatory T cell assays, complementary flow cytometry analysis should confirm the expression of other relevant markers like FOXP3 .

How can researchers effectively use recombinant IL2RA as a standard in quantitative assays like ELISA?

When utilizing recombinant IL2RA as a standard in quantitative assays such as ELISA, researchers should implement several methodological considerations. For sandwich ELISA, optimal results are achieved using capture antibody dilutions around 2 μg/mL and detector antibody dilutions at approximately 0.5 μg/mL. Serial dilutions of the recombinant protein should be prepared in appropriate buffer systems to generate reliable standard curves, typically spanning the range of 10-1000 pg/mL. Carrier-free formulations are preferred for quantitative assays to prevent interference from carrier proteins. Standard curves should be run in triplicate to account for pipetting variability, and appropriate negative controls must be included. Researchers should validate each new lot of recombinant IL2RA against previous standards to ensure inter-assay consistency. For measuring soluble IL2RA in biological fluids, samples should be diluted to fall within the linear range of the standard curve, and matrix effects should be evaluated and compensated for in the assay design .

What approaches can be used to study IL2RA interactions with other receptor components?

To study IL2RA interactions with other receptor components, researchers can employ multiple complementary approaches. Co-immunoprecipitation assays using tagged versions of IL2RA, IL2RB, and γc can reveal physical associations between these subunits. Surface plasmon resonance or biolayer interferometry provides quantitative binding kinetics of IL2RA with IL-2 and other receptor subunits. Monoclonal antibodies targeting specific epitopes, such as HIEI which interferes with IL2RA-IL2RB interactions, can be powerful tools to dissect the functional relationships between receptor subunits. Mutational analysis using recombinant proteins with specific amino acid substitutions (like the F42A IL-2 analog that binds only to IL2RB) can elucidate binding domains. FRET or BRET approaches using fluorescently tagged receptor subunits allow real-time visualization of complex formation in living cells. Researchers should employ multiple techniques to overcome the limitations of any single approach when studying these complex interactions .

How does IL2RA contribute to the affinity conversion model in IL-2 receptor signaling?

Contrary to the strict hierarchical IL-2-binding affinity conversion model previously proposed, IL2RA's role extends beyond merely concentrating IL-2 at the cell surface. Research using monoclonal antibody HIEI, which interferes with IL2RA-IL2RB interactions, demonstrates that IL2RA actively modifies IL2RB functionality. This interaction occurs independent of IL-2 binding to IL2RA, challenging the ordered sequence model where IL-2 must first bind IL2RA before interacting with IL2RB. The F42A IL-2 analog, which binds only to IL2RB but still maintains 75-100% of wild-type IL-2 bioactivity, further challenges this model. When HIEI blocks IL2RA-IL2RB interactions, researchers observe decreased affinity of F42A for IL2RB and inhibited proliferative effects. This suggests IL2RA contributes multiple functions to IL-2 signaling: concentrating IL-2 within the plasma membrane's two-dimensional surface and altering IL2RB's functional capacity by increasing its affinity for IL-2. This affinity conversion occurs without requiring prior IL-2 binding to IL2RA, revealing a more complex signaling mechanism than previously recognized .

What are the methodological approaches for investigating IL2RA's role in regulatory T cell biology?

Investigating IL2RA's role in regulatory T cell (Treg) biology requires sophisticated methodological approaches. Researchers should employ multiparameter flow cytometry to simultaneously assess IL2RA (CD25) expression alongside other Treg markers like FOXP3, CTLA-4, and CD127. For functional studies, in vitro suppression assays using purified CD4+CD25+ Tregs and CD4+CD25- responder T cells can quantify suppressive capacity. CRISPR-Cas9 genome editing of IL2RA in primary T cells or cell lines permits precise manipulation of expression or structure. Single-cell RNA sequencing reveals heterogeneity within IL2RA-expressing populations and identifies co-regulated gene networks. Conditional knockout models using Cre-lox systems allow tissue-specific or temporal deletion of IL2RA to dissect context-dependent functions. Phospho-flow cytometry can map downstream signaling events following IL-2 engagement with its receptor complex. These approaches should be combined with recombinant IL2RA proteins as controls or competitors to validate specificity of observed effects .

How can researchers effectively study soluble IL2RA (sIL2RA) in relation to membrane-bound forms?

To effectively study soluble IL2RA (sIL2RA) in relation to membrane-bound forms, researchers must employ multiple complementary approaches. Quantitative ELISAs using recombinant IL2RA as standards provide precise measurement of sIL2RA levels in biological fluids. Researchers should develop bioassays comparing the functional effects of recombinant sIL2RA versus membrane-bound forms on IL-2-dependent cellular responses. Western blotting with domain-specific antibodies can characterize structural differences between soluble and membrane-bound variants. Cell culture systems expressing cleavable versus non-cleavable IL2RA mutants help identify mechanisms regulating release of sIL2RA. Competitive binding studies using labeled IL-2 reveal whether sIL2RA acts primarily as an IL-2 sink or has distinct signaling properties. Proximity ligation assays can detect interactions between sIL2RA and membrane-bound receptor components. For clinical correlation studies, multivariate analysis should be employed to determine relationships between sIL2RA levels and markers of T and B cell activation in inflammatory conditions, leukemias, and lymphomas .

What are common pitfalls when working with recombinant IL2RA in binding studies?

Several common pitfalls can compromise binding studies using recombinant IL2RA. First, inadequate blocking of non-specific binding sites leads to high background signals and false-positive interactions. Researchers should optimize blocking conditions using both protein blockers (BSA, serum) and detergents at appropriate concentrations. Second, failing to account for the three different affinity states of the IL-2 receptor system (low, intermediate, and high) can result in misinterpretation of binding data. Each receptor configuration should be characterized independently, using cells expressing defined receptor components. Third, improper handling of recombinant proteins causes aggregation or denaturation that alters binding properties; proteins should be maintained in recommended buffers with stabilizers when appropriate. Fourth, neglecting the impact of tags (His, GST, Fc) on binding properties can introduce artifacts; control experiments with different tag configurations or tag-cleaved proteins are essential. Finally, pH and ionic strength significantly affect IL2RA interactions; buffer conditions should be systematically optimized and maintained consistently across experiments .

How can researchers address variability in recombinant IL2RA functional assays?

To address variability in recombinant IL2RA functional assays, researchers should implement several methodological controls and standardization practices. First, establish internal assay controls using reference standards with known activity levels to normalize results across experimental batches. Second, characterize each new lot of recombinant IL2RA through quality control assays including SDS-PAGE for purity assessment, functional binding assays, and bioactivity measurements. Third, optimize and standardize reconstitution procedures, as protein concentration and buffer composition significantly impact activity; document precise protocols including reconstitution buffers, protein concentrations, and incubation times. Fourth, account for the presence or absence of carrier proteins (e.g., BSA), as these can affect stability and activity; carrier-free versions may be preferable for certain applications despite potentially lower stability. Fifth, implement statistical approaches such as using technical replicates (minimum triplicates) and appropriate statistical tests to distinguish biological variation from technical noise. Finally, validate key findings using multiple recombinant IL2RA sources or alternative approaches to confirm biological relevance versus reagent-specific effects .

What technical considerations are important when measuring IL2RA-mediated signaling events?

When measuring IL2RA-mediated signaling events, several technical considerations are critical for generating reliable data. First, temporal dynamics are essential—IL-2 signaling involves rapid events occurring within minutes (JAK/STAT phosphorylation) and longer-term responses over hours to days (gene expression, proliferation). Researchers should design time-course experiments with appropriate resolution for the specific pathway under investigation. Second, cell population heterogeneity can mask signaling responses; flow cytometry or single-cell approaches should be employed to resolve signaling events in distinct cellular subsets. Third, the stoichiometry of receptor components significantly impacts signaling outcomes; researchers should quantify relative expression levels of IL2RA, IL2RB, and γc in their experimental system. Fourth, non-canonical signaling pathways beyond JAK/STAT, including MAPK and PI3K/Akt, contribute to IL-2 responses and should be concurrently assessed. Fifth, appropriate controls are critical—including stimulation with IL-2 mutants that selectively engage different receptor configurations (like F42A), and inhibitors targeting specific pathway components. Finally, researchers should validate antibody specificity for phospho-epitopes using phosphatase treatments and stimulation controls to prevent misinterpretation of signaling data .

How can recombinant IL2RA be used to develop diagnostic assays for immune-related conditions?

Recombinant IL2RA provides a critical tool for developing diagnostic assays for immune-related conditions. Researchers can create standardized ELISA systems using recombinant IL2RA as calibration standards to accurately quantify soluble IL2RA (sIL2RA) levels in patient samples. Elevated serum sIL2RA concentrations correlate with increased T and B cell activation in various inflammatory conditions, leukemias, and lymphomas. When developing such assays, researchers should establish reference ranges from healthy control populations, accounting for age, sex, and ethnicity variations. Multiplex assay platforms incorporating sIL2RA alongside other immune biomarkers can provide comprehensive immune profiles with greater diagnostic value than single-marker tests. Establishing clinically relevant cutoff values requires receiver operating characteristic (ROC) curve analysis with adequate sample sizes from well-characterized patient cohorts. Point-of-care testing formats using recombinant IL2RA-derived standards enable rapid assessment in resource-limited settings. For longitudinal monitoring applications, assay variability must be carefully controlled to distinguish true biological changes from technical variation .

What are the methodological approaches for studying IL2RA polymorphisms in disease associations?

To study IL2RA polymorphisms in disease associations, researchers should implement comprehensive methodological approaches. Genome-wide association studies (GWAS) can identify IL2RA genetic variants associated with autoimmune conditions, requiring large, well-characterized cohorts and appropriate statistical corrections for multiple testing. For functional characterization of identified variants, researchers should employ luciferase reporter assays with constructs containing promoter or enhancer regions to assess effects on transcriptional activity. CRISPR-based genome editing allows introduction of specific polymorphisms into cellular models to examine their impact on IL2RA expression and function. Flow cytometry quantification of IL2RA surface expression on different immune cell subsets from individuals with various genotypes can reveal cell-specific effects of polymorphisms. RNA sequencing analysis of cells from individuals with different IL2RA genotypes identifies downstream genes and pathways affected by variant expression. For clinical correlation, researchers should design longitudinal studies examining associations between IL2RA genotypes and disease progression, treatment response, or complications. These approaches require careful consideration of confounding variables and implementation of appropriate controls to establish causality rather than mere association .

How can recombinant IL2RA contribute to therapeutic development targeting the IL-2 pathway?

Recombinant IL2RA serves as an essential tool in therapeutic development targeting the IL-2 pathway through multiple applications. In drug discovery, researchers can use recombinant IL2RA in high-throughput screening assays to identify small molecules that modulate IL2RA-IL2 interactions or receptor complex formation. For antibody therapeutics, recombinant IL2RA provides a target for generating and screening monoclonal antibodies with desired functional properties (agonistic, antagonistic, or non-blocking). In protein engineering approaches, researchers can develop IL2RA-based fusion proteins or modified variants with enhanced stability, altered binding properties, or targeted tissue distribution. For mechanistic studies, recombinant IL2RA helps delineate the molecular basis of existing IL-2 pathway-targeting drugs like denileukin diftitox, aldesleukin, basiliximab, and daclizumab, providing insights for rational drug design. When developing IL2RA-targeting CAR-T cell therapies for cancer treatment, recombinant protein enables precise assessment of CAR binding specificity and functional responses. Comprehensive characterization of therapeutic candidates requires multiple complementary assays examining binding kinetics, receptor complex formation, signaling pathway activation, and functional cellular responses .